The circulating 70 kDa heat shock protein (HSPA1A) level is a potential biomarker for breast carcinoma and its progression
Carregando...
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE PORTFOLIO
Citação
SCIENTIFIC REPORTS, v.12, n.1, article ID 13012, 8p, 2022
Resumo
The early diagnosis of breast cancer can improve treatment and prognosis. We sought to evaluate whether the serum concentration of the 70 kDa heat shock protein (HSPA1A) was elevated in Brazilian women with breast cancer, and if levels correlated with tumor characteristics. This was a cross-sectional, analytical, case-control exploratory study performed at The University of Sao Paulo School of Medicine. From September 2017 to December 2018, 68 women with breast cancer and 59 controls were recruited. The HSPA1A concentration in serum samples was determined by ELISA by individuals blinded to the clinical data. The mean ages in the study and control groups were 54.9 and 52.0 years, respectively. The median serum levels of HSPA1A were elevated in women with breast cancer (1037 pg/ml) compared with controls (300 pg/ml) (p < 0.001). Elevated HSPA1A levels were associated with advanced histological tumor grade (p < 0.001) and with the cell proliferation index (KI67) (p = 0.0418). The HSPA1A concentration was similar in women with different histological subtypes, nuclear grade, hormone receptor expression, HER2 status and the presence or absence of angiolymphatic invasion. Elevated serum HSPA1A in Brazilian women with advanced histological grade and proliferation index breast cancer supports the potential value of additional investigation on larger and more varied populations to verify the value of HSPA1A detection as a component of breast cancer diagnosis and progression.
Palavras-chave
Referências
- Asea Alexzander, 2006, Current Immunology Reviews, V2, P209, DOI 10.2174/157339506778018514
- Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006
- Calderwood SK, 2012, J CELL BIOCHEM, V113, P1096, DOI 10.1002/jcb.23461
- Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082
- Ciocca DR, 2013, ARCH TOXICOL, V87, P19, DOI 10.1007/s00204-012-0918-z
- Coates AS, 2015, ANN ONCOL, V26, P1533, DOI 10.1093/annonc/mdv221
- Davidson B, 2016, HUM PATHOL, V54, P64, DOI 10.1016/j.humpath.2016.02.023
- DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203
- Dimas DT, 2018, ANTICANCER RES, V38, P1551, DOI 10.21873/anticanres.12384
- Gehrmann M, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00307
- Gehrmann M, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-131
- Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
- Guan YF, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.749673
- Gunaldi M, 2015, TOHOKU J EXP MED, V236, P97, DOI 10.1620/tjem.236.97
- Gunther S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00556
- INCA, 2020, CONC MAGN CANC MAM
- Kehdy FSG, 2015, P NATL ACAD SCI USA, V112, P8696, DOI 10.1073/pnas.1504447112
- Kirkwood BR, 2006, ESSENTIAL MED STAT, V2nd
- Lakhani SR., 2012, WHO CLASSIFICATION T
- Lazaris AC, 1997, BREAST CANCER RES TR, V43, P43, DOI 10.1023/A:1005706110275
- McCullagh P., 1989, GEN LINEAR MODELS, DOI 10.1007/978-1-4899-3242-6
- Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2
- Rothammer A, 2019, RADIAT ONCOL, V14, DOI 10.1186/s13014-019-1286-0
- Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
- Stangl S, 2018, CANCER RES, V78, P6268, DOI 10.1158/0008-5472.CAN-18-0707
- TAKAHASHI S, 1994, AM J CLIN PATHOL, V101, P519
- Thorsteinsdottir J, 2017, J NEURO-ONCOL, V135, P443, DOI 10.1007/s11060-017-2600-z
- VargasRoig LM, 1997, CANCER DETECT PREV, V21, P441
- Whitley D, 1999, J VASC SURG, V29, P748, DOI 10.1016/S0741-5214(99)70329-0
- World Health Organization, 2021, PUBL GLOB CANC OBS
- Zoppino FCM, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4621-1